Revvity Inc. has announced a strategic partnership with Element Biosciences Inc. to develop and commercialise an in vitro diagnostic (IVD) workflow solution for neonatal sequencing. The collaboration builds upon Revvity’s existing next-generation sequencing (NGS) workflow for newborn sequencing research and aims to strengthen Element’s regulatory approval pathway for their AVITI benchtop sequencing system.

The partnership represents a significant advancement in neonatal screening technology, combining Revvity’s expertise in newborn screening and rare disease detection with Element’s sequencing capabilities. The collaboration will initially provide researchers with immediate access to a research use only (RUO) version of the newborn sequencing workflow, whilst development continues on the comprehensive IVD solution.

“This strategic endeavour represents a significant step forward in our commitment to advancing newborn health through innovative genomic technologies,” says Yves Dubaquie, senior vice president of diagnostics at Revvity. “By combining our expertise in newborn screening and rare disease detection with Element’s technological capabilities, Revvity aims to deliver a robust, efficient, and accessible solution for neonatal sequencing in both research and clinical settings.”

The integrated workflow solution incorporates Revvity’s comprehensive suite of technologies, including sample collection devices, dried blood spot punchers, and automated nucleic acid extractors. The system also features liquid handlers, NGS library preparation kits with curated NGS panels, and comprehensive software for variant calling data analysis and interpretation.

Element’s contribution centres on their AVITI sequencing system, which is currently pursuing regulatory approval. Yaron Hakak, senior vice president of corporate and business development at Element, emphasised the significance of the collaboration: “Collaboration with Revvity on this IVD solution will provide a comprehensive, high-quality offering that meets the unique needs of newborn screening programs worldwide.”

The partnership marks an organic progression for both companies, expanding the application of Element’s AVITI sequencing system whilst enhancing the reach of Revvity’s newborn sequencing research workflow. The combined technologies aim to provide an end-to-end solution supporting both pioneering neonatal research and the development of IVD applications in this field.